SSY Group Secures Chinese Regulatory Approval for Bilastine and Sodium Picosulfate Bulk Drugs

SSY Group Ltd. has announced that it has received regulatory approval from the National Medical Products Administration of China for the registration of its bulk drugs Bilastine and Sodium Picosulfate. Bilastine is primarily used for the symptomatic treatment of urticaria, while Sodium Picosulfate is used for colon cleansing prior to surgical examinations such as colonoscopy. The approval allows these products to be prepared for market release. No other organizations were mentioned as recipients of this regulatory approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251204-11943644), on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)